Literature DB >> 11305075

Hydromorphone: pharmacology and clinical applications in cancer patients.

N Sarhill1, D Walsh, K A Nelson.   

Abstract

Hydromorphone is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low. The kidney excretes hydromorphone and its metabolites. Some metabolites may have greater analgesic activity than hydromorphone itself but are unlikely to contribute to the pharmacological activity of hydromorphone. With the exception of pruritus, sedation and nausea and vomiting, which may occur less after hydromorphone than after morphine, the side-effects of these drugs are similar. On a milligram basis hydromorphone is five times as potent as morphine when given by the oral route, and 8.5 times as potent as morphine when given intravenously.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11305075     DOI: 10.1007/s005200000183

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  27 in total

1.  Opioids in cancer pain--which one is best?

Authors:  C H Wilder-Smith
Journal:  Support Care Cancer       Date:  2001-03       Impact factor: 3.603

2.  Advertisement woes.

Authors:  George Vautour
Journal:  CMAJ       Date:  2005-12-06       Impact factor: 8.262

Review 3.  Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem.

Authors:  Kirsten Auret; Stephan A Schug
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 5.  Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.

Authors:  Linda L Liu; Michael A Gropper
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Pharmacological management of renal colic in the older patient.

Authors:  Blayne K Welk; Joel M H Teichman
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

8.  Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain.

Authors:  S Wirz; H C Wartenberg; J Nadstawek
Journal:  Support Care Cancer       Date:  2007-12-20       Impact factor: 3.603

Review 9.  Demographics, assessment and management of pain in the elderly.

Authors:  Mellar P Davis; Manish Srivastava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.

Authors:  George A Davis; Anita C Rudy; Sanford M Archer; Daniel P Wermeling; Patrick J McNamara
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.